Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

cafedrine/theodrenaline, urapidil

PreclinicalSmall molecule

UUniversity Hospital Schleswig-Holstein

cafedrine/theodrenaline, urapidil is one of 2 small molecule programs targeting Oxygenation. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

OxygenationWithdrawn

OxygenationPreclinical

Withdrawn

Competition

Competitive Landscape

3 competitors in Oxygenation

#DrugCompanyPhaseTrials

NORADRENALIN

UUniversity of Aarhus

cafedrine/theodrenaline, urapidil

UUniversity Hospital Schleswig-Holstein

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxygenation1 trial

Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation

Withdrawn·UUniversity Hospital Schleswig-Holstein·N/A·NCT01311414

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cafedrine/theodrenaline, urapidil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cafedrine/theodrenaline, urapidil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cafedrine/theodrenaline, urapidil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Schleswig-Holstein company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital Schleswig-Holstein

Related News